Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency

Allergy and Asthma Proceedings

Volumn 35, Issue 3, 2014, Pages 255-259

  Farkas, Henriette ^a   Csuka, Dorottya ^a   Veszeli, Nóra ^a   Zotter, Zsuzsanna ^a   Szabó, Erika ^a   Varga, Lilian ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1S INHIBITOR; RECOMBINANT PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; C1 INHIBITOR DEFICIENCY; COMPLEMENT DEFICIENCY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENERAL CONDITION IMPROVEMENT; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; PATIENT SATISFACTION; RECURRENT DISEASE; SUBCUTANEOUS TISSUE; SUBMUCOSA; SYSTEMIC DISEASE; TISSUE DISTRIBUTION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; DISEASE COURSE; HEREDITARY ANGIOEDEMA TYPES I AND II; INFUSION; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; COMPLEMENT C1 INHIBITOR PROTEIN; DISEASE PROGRESSION; HEREDITARY ANGIOEDEMA TYPES I AND II; HOME INFUSION THERAPY; HUMANS; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84899812082     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2014.35.3743     Document Type: Article

References (22)

1. Farkas H. Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opin Pharmacother 14:571-586, 2013.
2. Kaplan AP. Bradykinin and the pathogenesis of hereditary angioedema. World Allergy Organ J 4:73-75, 2011.
3. Longhurst H, and Cicardi M. Hereditary angio-oedema. Lancet 379:474-481, 2012.
4. Agostoni A, Aygören-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114(suppl):S51-S131, 2004. (Pubitemid 39200689)
5. Bernstein JA. HAE update: Epidemiology and burden of disease. Allergy Asthma Proc 34:3- 6, 2013.
6. Caballero T, Aygören-Pürsün E, Bygum A, et al. The humanistic burden of hereditary angioedema: Results from the Burden of Illness Study in Europe. Allergy Asthma Proc 35:47-53, 2014.
7. Cicardi M, Bork K, Caballero T, et al.; HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy 67:147-157, 2012.
8. Craig T, Aygören-Pürsün E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 5:182-199, 2012.
9. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6:24, 2010.
10. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 6:22, 2010.
11. Bork K, and Davis-Lorton M. Overview of hereditary angioedema caused by C1-inhibitor deficiency: Assessment and clinical management. Eur Ann Allergy Clin Immunol 45:7-16, 2013.
12. Zanichelli A, Mansi M, Periti G, and Cicardi M. Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency. Expert Rev Clin Immunol 9:477- 488, 2013.
13. Kalaria S, and Craig T. Assessment of hereditary angioedema treatment risks. Allergy Asthma Proc 34:519 -522, 2013.
14. Bork K, Steffensen I, and Machnig T. Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: A systematic literature review. Allergy Asthma Proc 34:312-327, 2013.
15. Varga L, and Farkas H. rhC1INH: A new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol 7:143-153, 2011.
16. Riedl MA, Levy RJ, Suez D, et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: A North American open-label study. Ann Allergy Asthma Immunol 110:295-299, 2013.
17. Moldovan D, Reshef A, Fabiani J, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy 42:929 -935, 2012.
18. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 126:821- 827.e14, 2010.
19. Reshef A, Moldovan D, Obtulowicz K, et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: A pilot study. Allergy 68:118 -124, 2013.
20. van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 116:876-883, 2005. (Pubitemid 41400555)
21. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 47:1028 -1032, 2007.
22. Hack CE, Relan A, Baboeram A, et al. Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: Evaluation of IgE antibodies. Clin Drug Investig 33:275-281, 2013.